Pharming Group NV
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Fabrice Chouraqui
- Full Time Employees
- 407
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Darwinweg 24 Leiden ZH Netherlands 2333 CR
- IPO Date
- Jul 2, 1998
- Website
- pharming.com
- Similar Companies
- Business
- Pharming Group N.V. (Euronext Amsterdam: PHARM; Nasdaq: PHAR) is a global biopharmaceutical company that develops, manufactures and commercializes protein replacement therapies and precision medicines for rare, ultra-rare and life-threatening diseases; its lead products include RUCONEST (conestat alfa), a recombinant C1 esterase inhibitor for treatment of acute hereditary angioedema attacks in adult and adolescent patients, and JOENJA (leniolisib), an oral small molecule PI3Kδ inhibitor for activated phosphoinositide 3-kinase delta syndrome in patients 12 years and older; the company advances a pipeline encompassing label expansions for pediatric indications and potential new uses in primary immunodeficiencies with immune dysregulation, alongside an ex-vivo autologous hematopoietic stem cell gene therapy (OTL-105) for hereditary angioedema through strategic collaboration with Orchard Therapeutics plc. Founded in 1988 and headquartered in Leiden, the Netherlands, with U.S. operations in Warren, New Jersey, Pharming serves patients in over 30 markets across North America, Europe, the Middle East, Africa and Asia-Pacific. Recent developments include the full acquisition of Abliva AB in early 2025, adding KL1333, a clinical-stage therapy for primary mitochondrial diseases with U.S. launch potential in 2028; advancement of supplemental New Drug Application for pediatric leniolisib approval expected in first-half 2026; a 15% reduction in general and administrative expenses totaling US$10 million announced in May 2025 to optimize capital allocation; and upward revision of full-year 2025 revenue guidance to US$365-375 million amid 30% third-quarter revenue growth to US$97.3 million driven by 35% increase in JOENJA sales.
Company News
Pharming Group announces third quarter 2026 revenues above market expectations
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes
Pharming announces CEO transition
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
MAC Alpha Capital Management LP Makes New $29.84 Million Investment in Pharming Group N.V. Sponsored ADR $PHAR
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Ratio makes improved bid for Pharos Energy
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Pharming Group N.V. (PHAR) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G.
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)